Dopamine agonist therapy in early Parkinson's disease

Stowe, Rebecca; Ives, Natalie; Clarke, Carl E; Hilten, JJ van; Ferreira, Joaquim J.; Hawker, R J; Shah, Laila; Wheatley, Keith; Gray, Richard

doi:10.1002/14651858.cd006564.pub2

Cited by 145 publications

(115 citation statements)

References 44 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…Sedation, nausea, and vomiting can occur but are rarely dose limiting 14 Dyskinesias and motor fluctuations (including the wearing off phenomenon and unpredictable on/off fluctuations) 6 occur in about 40% of patients after five years of treatment. 15 Risk is higher for young onset Parkinson's disease (90% within five years), longer disease duration, and higher levodopa doses.…”

Section: Levodopamentioning

confidence: 99%

See 1 more Smart Citation

Initial drug treatment in Parkinson’s disease:

Muzerengi

Clarke

2015

BMJ

Self Cite

View full text Add to dashboard Cite

Section: Levodopamentioning

confidence: 99%

“…Dopamine agonists compared with placebo or levodopa: nausea (NNH=9), somnolence (NNH=8), oedema, (NNH=9), dizziness (NNH=15), vomiting (NNH=34), hallucinations (NNH=22), and hypotension (NNH=48) 6 Impulse control disorders: NNH 10 for patients taking dopamine agonists compared with those not taking dopamine agonists over six months 17…”

Section: Dopamine Agonistsmentioning

confidence: 99%

Initial drug treatment in Parkinson’s disease:

Muzerengi

Clarke

2015

BMJ

Self Cite

View full text Add to dashboard Cite

“…P=0.01), dizziness (1.45, 1.09 to 1.92; P=0.01), hallucinations (1.69, 1.13 to 2.52; P=0.01), and nausea (1.32, 1.05 to 1.66; P=0.02) 98. …”

mentioning

confidence: 94%

Initial management of Parkinson's disease

Goetz

Pal

2014

BMJ

View full text Add to dashboard Cite

Parkinson's disease is one of the most common neurodegenerative disorders seen in the United States and United Kingdom. The disease is characterised by two processes-cellular degeneration and the resulting biochemical deficiency of dopamine. Although these processes are inter-related, they are approached separately in the clinical setting. Currently, no proven neuroprotective or disease modifying treatment is available for Parkinson's disease. Several agents can be used to treat the motor symptoms associated with dopamine deficiency, and it is important to choose wisely when starting treatment. Drugs can have mild, moderate, or high potency, and the patient's goals, comorbidities, and the short and long term implications of choosing a specific agent should be taken into account when selecting the appropriate agent. Non-motor symptoms, such as depression, fatigue, and disorders of sleep and wakefulness, also need to be evaluated and treated. Research is under way to deliver dopaminergic therapy more effectively, but studies aimed at slowing or stopping disease progression have not shown promise.

show abstract

“…A different study found a prevalence of hallucinations on antiparkinsonian medication in patients with PD of 46.3% and illusions of 16% 1. Two recent meta-analyses have demonstrated that hallucinations are more frequent among patients with early PD randomised to dopaminergic treatment compared with placebo 3. The most common delusions in patients with PD are paranoid.…”

Section: Introductionmentioning

confidence: 99%

Visual hallucinations in photographs in Parkinson's disease

2013

View full text Add to dashboard Cite

SUMMARYVisual hallucinations are reported in 16-37% of drugtreated patients with Parkinson's disease (PD) and are the most common hallucinations in PD. We report two patients with PD with symptoms that uniquely integrate visual hallucinations and delusions. We report two cases of patients with PD with visual hallucinations who saw the persistence of these hallucinations in photographs. These pictures were taken to prove the absence of these hallucinations. We believe this is the first description of this peculiar phenomenon, in which hallucinations or illusions could be replicated in photographs. Both patients had delusions associated with the images and we speculate that the images they saw in the photographs represent a further delusion, hence a 'delusional hallucination' or 'delusional illusion. ' We believe that delusions fostering hallucinations are rare. BACKGROUND

show abstract

Dopamine agonist therapy in early Parkinson's disease

Cited by 145 publications

References 44 publications

Initial drug treatment in Parkinson’s disease:

Initial drug treatment in Parkinson’s disease:

Initial management of Parkinson's disease

Visual hallucinations in photographs in Parkinson's disease

Contact Info

Product

Resources

About